Literature DB >> 6321690

Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration.

P E Postmus, J J Holthuis, H Haaxma-Reiche, N H Mulder, L M Vencken, W J van Oort, D T Sleijfer, H J Sluiter.   

Abstract

VP 16-213 in standard doses is active against a number of solid tumors. Its penetration into the cerebrospinal fluid (CSF) is very limited at these dose levels. In 10 patients treated with high-dose VP 16-213 (0.9-2.5 g/m2), CSF levels of up to 0.54 microgram/mL were detected. In two patients with central nervous system (CNS) metastases of small cell lung cancer (SCLC) a response was seen after 1.0 and 1.5 g/m2 intravenously. High-dose VP 16-213 can possibly play a role in the treatment of CNS metastases of SCLC. Its application in late intensification regimens as a form of prophylaxis of CNS metastases should be investigated.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6321690     DOI： 10.1200/JCO.1984.2.3.215

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


  23 in total

1.  Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data.

Authors:  A van der Gaast; P Sonneveld; D R Mans; T A Splinter
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Etoposide phosphate, the water soluble prodrug of etoposide.

Authors:  A H Witterland; C H Koks; J H Beijnen
Journal:  Pharm World Sci       Date:  1996-10

3.  Pre-irradiation intensive induction and marrow-ablative consolidation chemotherapy in young children with newly diagnosed high-grade brainstem gliomas: report of the "head-start" I and II clinical trials.

Authors:  Diana S Osorio; Neha Patel; Lingyun Ji; Richard Sposto; Joseph Stanek; Sharon L Gardner; Jeffrey C Allen; Albert Cornelius; Geoffrey B McCowage; Amanda Termuhlen; Ira J Dunkel; Melanie Comito; James Garvin; Jonathan L Finlay
Journal:  J Neurooncol       Date:  2018-11-03       Impact factor: 4.130

Review 4.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

5.  Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors.

Authors:  Luciano Scopece; Enrico Franceschi; Giovanna Cavallo; Anna Paioli; Gabriele Paioli; Rosa Conforti; Emanuela Palmerini; Carlotta Berzioli; Federica Spagnolli; Roberta Degli Esposti; Lucio Crinò
Journal:  J Neurooncol       Date:  2006-04-28       Impact factor: 4.130

6.  Clinical pharmacology of intracarotid etoposide.

Authors:  N Savaraj; L G Feun; K Lu; S Wallace; W S Fields; T L Loo
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Treatment of intracranial nongerminomatous germ-cell tumor by high-dose chemotherapy and autologous stem-cell rescue.

Authors:  T Tada; T Takizawa; F Nakazato; S Kobayashi; K Koike; M Oguchi; E Ishii; Y Amano
Journal:  J Neurooncol       Date:  1999-08       Impact factor: 4.130

8.  Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide.

Authors:  K H Pflüger; L Schmidt; M Merkel; H Jungclas; K Havemann
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors.

Authors:  Irene Slavc; Elisabeth Schuller; Jutta Falger; Mehmet Günes; Konrad Pillwein; Thomas Czech; Wolfgang Dietrich; Karl Rössler; Karin Dieckmann; Daniela Prayer; Johannes Hainfellner
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

10.  Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma.

Authors:  E Franceschi; G Cavallo; L Scopece; A Paioli; A Pession; E Magrini; R Conforti; E Palmerini; S Bartolini; S Rimondini; R Degli Esposti; L Crinò
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.